Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice
Cédric Louvet, Gregory L. Szot, Jiena Lang, et al.
Proceedings of the National Academy of Sciences (2008) Vol. 105, Iss. 48, pp. 18895-18900
Open Access | Times Cited: 214

Showing 1-25 of 214 citing articles:

Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
David G. DeNardo, Donal J. Brennan, Elton Rexhepaj, et al.
Cancer Discovery (2011) Vol. 1, Iss. 1, pp. 54-67
Open Access | Times Cited: 1638
Genetics, pathogenesis and clinical interventions in type 1 diabetes
Jeffrey A. Bluestone, Kevan C. Herold, George S. Eisenbarth
Nature (2010) Vol. 464, Iss. 7293, pp. 1293-1300
Open Access | Times Cited: 1160
IRE1α Kinase Activation Modes Control Alternate Endoribonuclease Outputs to Determine Divergent Cell Fates
Dan Han, Alana G. Lerner, Lieselotte Vande Walle, et al.
Cell (2009) Vol. 138, Iss. 3, pp. 562-575
Open Access | Times Cited: 761
The unfolded protein response signals through high-order assembly of Ire1
Alexei Korennykh, Pascal F. Egea, А.A. Коростелев, et al.
Nature (2008) Vol. 457, Iss. 7230, pp. 687-693
Open Access | Times Cited: 636
Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
Javid J. Moslehi, Michael W. Deininger
Journal of Clinical Oncology (2015) Vol. 33, Iss. 35, pp. 4210-4218
Open Access | Times Cited: 404
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes
Thomas Force, Kyle L. Kolaja
Nature Reviews Drug Discovery (2011) Vol. 10, Iss. 2, pp. 111-126
Closed Access | Times Cited: 348
Understanding, recognizing, and managing toxicities of targeted anticancer therapies
Grace K. Dy, Alex A. Adjei
CA A Cancer Journal for Clinicians (2013) Vol. 63, Iss. 4, pp. 249-279
Open Access | Times Cited: 313
New Frontiers in the Treatment of Type 1 Diabetes
Jeremy Warshauer, Jeffrey A. Bluestone, Mark S. Anderson
Cell Metabolism (2019) Vol. 31, Iss. 1, pp. 46-61
Open Access | Times Cited: 199
Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association
Umberto Campia, Javid J. Moslehi, Laleh Amiri‐Kordestani, et al.
Circulation (2019) Vol. 139, Iss. 13
Open Access | Times Cited: 168
Fibroblast activation and myofibroblast generation in obstructive nephropathy
María T. Grande, José M. López‐Novoa
Nature Reviews Nephrology (2009) Vol. 5, Iss. 6, pp. 319-328
Closed Access | Times Cited: 254
Restoring endoplasmic reticulum function by chemical chaperones: an emerging therapeutic approach for metabolic diseases
Feyza Engin, Gökhan S. Hotamışlıgil
Diabetes Obesity and Metabolism (2010) Vol. 12, Iss. s2, pp. 108-115
Closed Access | Times Cited: 237
Selectivity and therapeutic inhibition of kinases: to be or not to be?
Kamran Ghoreschi, Arian Laurence, John J. O’Shea
Nature Immunology (2009) Vol. 10, Iss. 4, pp. 356-360
Open Access | Times Cited: 224
Abnormal Angiogenesis in Diabetic Nephropathy
Takahiko Nakagawa, Tomoki Kosugi, Masakazu Haneda, et al.
Diabetes (2009) Vol. 58, Iss. 7, pp. 1471-1478
Open Access | Times Cited: 187
Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics
Hui Cheng, Thomas Force
Circulation Research (2010) Vol. 106, Iss. 1, pp. 21-34
Open Access | Times Cited: 186
Comparative Analysis Reveals Conserved Protein Phosphorylation Networks Implicated in Multiple Diseases
Chris Soon Heng Tan, Bernd Bodenmiller, Adrian Pasculescu, et al.
Science Signaling (2009) Vol. 2, Iss. 81
Closed Access | Times Cited: 186
Current Advances and Travails in Islet Transplantation
David M. Harlan, Norma S. Kenyon, Olle Korsgren, et al.
Diabetes (2009) Vol. 58, Iss. 10, pp. 2175-2184
Open Access | Times Cited: 183
Vascular and Metabolic Implications of Novel Targeted Cancer Therapies
Weijuan Li, Kevin Croce, David P. Steensma, et al.
Journal of the American College of Cardiology (2015) Vol. 66, Iss. 10, pp. 1160-1178
Open Access | Times Cited: 173
Targeting ABL-IRE1α Signaling Spares ER-Stressed Pancreatic β Cells to Reverse Autoimmune Diabetes
Shuhei Morita, S. Armando Villalta, Hannah C. Feldman, et al.
Cell Metabolism (2017) Vol. 25, Iss. 5, pp. 1207-1207
Open Access | Times Cited: 156
Targeting ABL-IRE1α Signaling Spares ER-Stressed Pancreatic β Cells to Reverse Autoimmune Diabetes
Shuhei Morita, S. Armando Villalta, Hannah C. Feldman, et al.
Cell Metabolism (2017) Vol. 25, Iss. 4, pp. 883-897.e8
Open Access | Times Cited: 156
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice
Nicole M Agostino, Vernon M. Chinchilli, Christopher J. Lynch, et al.
Journal of Oncology Pharmacy Practice (2010) Vol. 17, Iss. 3, pp. 197-202
Closed Access | Times Cited: 150
Immunotherapy of Type 1 Diabetes: Where Are We and Where Should We Be Going?
Xunrong Luo, Kevan C. Herold, Stephen D. Miller
Immunity (2010) Vol. 32, Iss. 4, pp. 488-499
Open Access | Times Cited: 136
The Role of Blood Vessels, Endothelial Cells, and Vascular Pericytes in Insulin Secretion and Peripheral Insulin Action
Oliver C. Richards, Summer M. Raines, Alan Attie
Endocrine Reviews (2010) Vol. 31, Iss. 3, pp. 343-363
Open Access | Times Cited: 128
Beta Cell Dedifferentiation Induced by IRE1α Deletion Prevents Type 1 Diabetes
Hugo Lee, Yong-Syu Lee, Quincy Eckert Harenda, et al.
Cell Metabolism (2020) Vol. 31, Iss. 4, pp. 822-836.e5
Open Access | Times Cited: 112
Cardio-Oncology
Andrew M. Bellinger, Carlos L. Arteaga, Thomas Force, et al.
Circulation (2015) Vol. 132, Iss. 23, pp. 2248-2258
Open Access | Times Cited: 109
Off-target effects of BCR–ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia
Juan Luis Steegmann, Francisco Cervantes, Philipp le Coutre, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2012) Vol. 53, Iss. 12, pp. 2351-2361
Closed Access | Times Cited: 107
Page 1 - Next Page

Scroll to top